-
Mashup Score: 68Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782 - 11 month(s) ago
Somatic tumor mutational burden (TMB) may result in formation of neoantigens that increase the likelihood of tumor cell recognition by infiltrating immune cells and has shown predictive value of response to immunotherapy agents that promote T-cell activation [1]. TMB assessed using tissue (tTMB) is predictive of response to pembrolizumab monotherapy in advanced solid tumors, including nonsquamous non–small cell lung cancer (NSCLC), with response enrichment in high tTMB (cutoff ≥ 175 mutations/exome using whole exome sequencing; equivalent to ≥ 10 mutations/megabase on the clinically validated FoundationOne® CDx) [1–3].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs https://t.co/lN60HDJLx7
-
-
Mashup Score: 0Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer - 2 year(s) ago
Abstract. Purpose: We sought to identify features of patients with advanced non-small cell lung cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors (ICIs), and how these might differ from features predictive of short-term response (STR). Experimental Design: We performed a multicenter retrospective analysis of patients with advanced NSCLC treated with ICIs over ten…
Categories: Hem/Oncs, Latest HeadlinesTweet-
What are the characteristics of patients with NSCLC and long-term response to immunotherapy? Retrospective report @CCR_AACR showed long-term response (8% of 3118) associated with high #TMB, non-squamous histology, depth of response, not PD-L1 expression. https://t.co/sJUQ2nqS4s
-
-
Mashup Score: 2Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsDavid R. GandaraDivision of Hematology/Oncology, Department of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CADavid R. Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner, Miles Cameron Andrews, Amit Mahipal, Vivek Subbiah, Ramez Nassef Eskander, David Paul Carbone, Jeremy Snider, Lilia Bouzit, Cheryl D. Cho-Phan, Megan Price, Gerald Li, Julia C. F. Quintanilha, Richard…
Source: meetings.asco.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The role of TMB across multiple tumor types further characterized in new data presented at #ASCO23: https://t.co/MFv3M5VQgW For more information about our #TMB harmonization project visit: https://t.co/p0XvuoO8e7
-
-
Mashup Score: 0Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs
-
-
Mashup Score: 1Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi9ap8 #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs
-
-
Mashup Score: 0Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs https://t.co/B0cdYRtVxX
-
-
Mashup Score: 1
Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Shoutout to @DrHendifar @KlempnerSam among 1st cases of an acquired TMZ-induced, truncating MSH6 mut resulting in high #TMB w/durable response to #PD-1 in high-grade #NEN @JCOPO_ASCO https://t.co/MRvfvlZowx @CSCancerCenter @TumorBoardTues https://t.co/4F6vkIdK8D https://t.co/u9fYqlqm2f
-
-
Mashup Score: 10Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 2 year(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Adding to the story of #TMB, this time across a large cohort of #SolidTumors #RWE #OutcomesAnalysis - Great to collaborate with the fantastic team @TempusLabs @JPatelMD Paper now out: https://t.co/BBG5W4j8nq @JAMANetworkOpen @mtmdphd @PC3Innovation @PennPrecisMed @PennCancer https://t.co/pKYUO0zvrf
-
Is there a predictive role for blood based #TMB and chemo-immunotherapy in NSCLC? KEYNOTE 782 results @LungCaJournal show that bTMB was NOT associated with PFS or OS for 1L platinum + pemetrexed + pembrolizumab in NSCLC. @JairBar4 @delvysra @dr_ponce_aix https://t.co/OxADznAT7P